Keywords
Psychiatry ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

782 Search results.

WHO-5 - WHO (Five) Well-Being Index

- 4/22/18 - 1 form, 1 itemgroup, 5 items, 30 languages
Itemgroup: Over the last two weeks
WHO (Five) Well-Being Index (1998 version) http://www.who-5.org Also called : WHO Five, WHO 5

Measurement Instrument Database for the Social Science (MIDSS) - Child Eating Behaviour Questionnaire (CEBQ)

- 6/25/20 - 1 form, 2 itemgroups, 36 items, 1 language
Itemgroups: Administrative documentation, Child Eating Behaviour Questionnaire (CEBQ)
Wardle, J., Guthrie, C. A., Sanderson, S., & Rapoport, L. (2001). Child Eating Behaviour Questionnaire (CEBQ). Measurement Instrument Database for the Social Science. Retrieved 25.06.2020, from www.midss.ie Key references: Wardle, J., Guthrie, C. A., Sanderson, S., & Rapoport, L. (2001). Development of the children’s eating behaviour questionnaire. Journal of Child Psychology and Psychiatry, 42, 963-970. Carnell, S., & Wardle, J. (2007). Measuring behavioural susceptibility to obesity: Validation of the child eating behaviour questionnaire. Appetite, 48, 104-113. Primary use / Purpose: The CEBQ is designed to measure eating styles in young children. Background: Research has suggested that individual differences in several aspects of eating style contribute to the development of weight problems in children and adults. The Child Eating Behaviour Questionnaire (CEBQ) was designed to assess children's eating scale styles. It is a parent-report measure comprised of 35 items, each rated on a five-point likert scale that ranges from never to always. It is made up of eight scales: Food responsiveness, Emotional over-eating, Enjoyment of food, Desire to drink, Satiety responsiveness, Slowness in eating, Emotional under-eating, and Food fussiness. The instrument is ideal for use in research investigating the early precursors of eating disorders or obesity. Psychometrics: The psychometric properties of the instrument have been evaluated by Wardle and colleagues (2001) and Carnell and Wardle (2007). Scoring: see https://www.midss.org/content/child-eating-behaviour-questionnaire-cebq (cited 25.06.2020) Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.271

Measurement Instrument Database for the Social Science (MIDSS) - Illness/Injury Sensitivity Index-Revised

- 6/25/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Administrative documentation, Illness/Injury Sensitivity Index-Revised
Carleton, R. N., Park, I. P., & Asmundson, G. J. G. (2006). Illness/Injury Sensitivity Index-Revised. Measurement Instrument Database for the Social Science. Retrieved 25.06.2020, from www.midss.ie Key references: Taylor, S. (1993). The structure of fundamental fears. Journal of Behavior Therapy and Experimental Psychiatry, 24, 289–299. doi: 10.1016/0005-7916(93)90053-Y Carleton, R. N., Asmundson, G.J.G., & Taylor, S. (2005). Fear of physical harm: Factor structure and psychometric properties of the Injury/Illness Sensitivity Index. Journal of Psychopathology and Behavioral Assessment, 27, 235–241. doi: 10.1007/s10862-005-2403-y Carleton, R. N., Park, I. P., & Asmundson, G. J. G. (2006). The Illness/Injury Sensitivity Index: An examination of construct validity. Depression and Anxiety, 23, 340-346. doi: 10.1002/da.20138 Primary use / Purpose: The Illness/Injury Sensitivity Index-Revised (ISI-R) is 9-item revision of the original Illness/Injury Sensitivity Index (Taylor, 1993) designed to measure fears of illness and injury (e.g., I worry about my physical health). Items are rated on a 5-point Likert scale ranging from 0 (agree very little) to 4 (agree very much). Background: Two factors, Fear of Illness (e.g., I worry about becoming physically ill) and Fear of Injury (e.g., I am frightened of being injured), are represented within the Illness/Injury Sensitivity Index-Revised (ISI-R; Carleton, Asmundson, & Taylor, 2005); however, the total summed score is used in most analyses. Psychometrics: The ISI-R has been shown to have excellent internal consistency (α=.86), convergent validity with other measures related to injury and illness (r>.65), and correlates highly with the original index, r=.96 (Carleton, Park, & Asmundson, 2006). Other Information: Scoring: Fear of Illness Subscale: items 3,4,6,7,8 Fear of Injury Subscale: items 1,2,5,9 Total score is often used, however. Items 7 & 8 from original measure are removed from this revised version Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.250

Eligibility Late Life Depression NCT01908673

- 6/14/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Automatic Self Transcending Meditation (ASTM) Versus Heart Rate Variability (HRV) Biofeedback in Patients With Late Life Depression (LLD): a Longitudinal Pilot Feasibility Study; ODM derived from: https://clinicaltrials.gov/show/NCT01908673

Eligibility Depression NCT01370304

- 4/25/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder; ODM derived from: https://clinicaltrials.gov/show/NCT01370304

Eligibility Schizophrenia NCT02086162

- 4/19/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Randomized Controlled Trial (RCT) of a Motivational Decision Support System; ODM derived from: https://clinicaltrials.gov/show/NCT02086162

Eligibility Impulsivity NCT01770600

- 4/16/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01770600

Eligibility Genetic High Risk for Schizophrenia NCT01943175

- 12/20/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01943175

Eligibility First Episode Schizophrenia NCT02088983

- 12/17/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT02088983

Eligibility Dysthymic Disorder NCT01537068

- 11/29/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Desvenlafaxine vs. Placebo Treatment of Chronic Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01537068

Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder; NCT00896363 - Psychiatric History

- 11/17/19 - 1 form, 2 itemgroups, 92 items, 1 language
Itemgroups: Psychiatric History, Psychiatric History, Mental disorder, Other
Study ID: 109035 Clinical Study ID: 109035 Study Title: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects With Major Depressive Disorder Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00896363 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK163090 1 mg, GSK163090 Placebo, GSK163090 3 mg Trade Name: Study Indication: Depressive Disorder

Polysomnographic Assessment of Vestipitant for the Treatment of Primary Insomnia NCT00992160 - Possible Suicidality-Related Adverse Event

- 11/12/19 - 1 form, 9 itemgroups, 28 items, 1 language
Itemgroups: Administrative Data, General information on possible suicidality-related AE, Suicidality-Related Adverse Event description, Possible suicidality-related adverse event causes, Psychiatric History, Psycho-social stressors, Suicidal ideation, Suicidal behaviour during study, Medical and psychiatric treatment
Study ID: 111364 Clinical Study ID: 111364 Study Title: A 28-Day, Polysomnographic and subjective assessment of Vestipitant (15mg/day) for the treatment of Primary Insomnia in adult Outpatients Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992160 Clinicaltrials.gov Links: https://clinicaltrials.gov/ct2/show/NCT00992160 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Vestipitant, Placebo Trade Name: N/A Study Indication: Primary Insomnia, Sleep Disorders This phase II, placebo-controlled, double-blind trial studies the polysomnographic and subjective effect of the neurokinin (NK1) antagonist vestipitant (15mg/day at bedtime) for the treatment of primary insomnia in adult outpatients over a period of four weeks. The study consists of a clinical Screening Visit (Visit 1), up to 21 days before investigational product/placebo initiation, two screening polysomnographies (Visits 2 and 3), followed by a placebo run-in until Visit 4, at which the subject is randomized to vestipitant or placebo, taken every night for 28 days. On Day 1 and 2 (Visits 4 and 5), polysomnographies are performed. Visit 6 is a safety visit on Day 15. On Day 27 and 28, Visits 7 and 8 are performed, which again include polysomnography studies. Subjects then undergo a 7 to 10 day placebo run-out period and have Day 7 and Day 14 Follow-Up Visit (Visits 9 and 10). This form is used to record details about any possible suicidality-related adverse events happening during the study. The event must also be reported on the Adverse Events Form (Non-serious or Serious Adverse Events form as applicable) using the same terminology. Record only 1 event per form.